21002 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
USES OF PTHRP ANALOGUE IN REDUCING FRACTURE RISK
#2TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS
#3FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE
#4POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY
#5PTH Treatment Regimen Comprising Two PTH Compounds
#6Liquid pharmaceutical formulations of PTH Conjugates
#7REJUVENATING THE AGED SKELETAL MICROENVIRONMENT TO REVERSE AGE-RELATED BONE LOSS
#8METHODS OF IMPROVING SPINAL FUSION WITH ABALOPARATIDE
#9USES OF PTHRP ANALOGUE IN REDUCING FRACTURE RISK
#10ORAL PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF OSTEOPOROSIS CONTAINING TERIPARATIDE AND METHOD FOR PREPARATION THEREOF
#11PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#12ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME
#13Controlled-Release PTH Compound
#14MICRONEEDLE COMPRISING PEPTIDE-BASED ACTIVE INGREDIENT AND FORMULATION COMPOSITION FOR MANUFACTURING SAME
#15TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS
#16PTH Prodrugs
#17Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) Inhibitors
#18ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME
#19LONG-ACTING PARATHYROID HORMONE
#20USES OF PTHRP ANALOGUE IN REDUCING FRACTURE RISK
#21VIRAL VECTORS ENCODING PARATHYROID HORMONE FUSIONS AND USES THEREOF IN TREATING HYPOPARATHYROIDISM
#22FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE
#23FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
#24MICRONEEDLE FORMULATION, MICRONEEDLE PATCH, AND PREPARATION METHODS THEREOF
#25DEVICE, SYSTEM AND METHODS FOR THE ORAL DELIVERY OF THERAPEUTIC COMPOUNDS
#26USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA
#27METHOD OF IMPROVING THE VIABILITY OF A DENTAL IMPLANT
#28ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME
#29PARATHYROID HORMONE COMPOUNDS IN THE TREATMENT OF HYPOPARATHYROIDISM
#30A COMPOSITION COMPRISING NANOSIZED ACTIVE PHARMACEUTICAL INGREDIENT
#31TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS
#32SWALLOWABLE DRUG DELIVERY DEVICE AND METHODS OF DRUG DELIVERY
#33FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
#34Neuronal diencephalon stem cells and exosomes thereof for the treatment and prevention of diseases
#35FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
#36FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS
#37MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS
#38Long-acting PTH compound treatments
#39ABALOPARATIDE FORMULATIONS AND METHODS OF TESTING, STORING, MODIFYING, AND USING SAME
#40NANOFIBER SHEET FOR HEALING TEAR OF ROTATOR CUFF CONTAINING RECOMBINANT PARATHYROID HORMONE AND METHOD FOR MANUFACTURING THE SAME
#41SOLVENT-CAST MICROPROTRUSION ARRAYS CONTAINING ACTIVE INGREDIENT
#42PROCESS OF MAKING ABALOPARATIDE
#43COMPOSITIONS AND METHODS TO SUPPRESS TUMOR GROWTH IN BONE, PREVENT CACHECTIC MUSCLE LOSS, AND PRESERVE SKELETAL INTEGRITY
#44COMPOSITIONS AND METHODS FOR TREATING ALZHEIMERS DISEASE
#45Controlled-release PTH compound
#46Treatment of Moderate-to-Severe Osteogenesis Imperfecta
#47Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
#48PROCESS OF MAKING ABALOPARATIDE
#49TREATMENT OF HYPOPARATHYROIDISM
#50PTH Compounds with Low Peak-To-Trough Ratios
#51METHODS OF TREATING A CARDIOVASCULAR ISCHEMIC EVENT
#52Long-acting parathyroid hormone
#53PTH prodrugs
#54POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY
#55ORAL POLYPEPTIDE FORMULATIONS
#56METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT
#57Device, system and methods for the oral delivery of therapeutic compounds
#58LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGS
#59GRK2 INHIBITION BY PAROXETINE AMELIORATES OSTEOARTHRITIS
#60Compounds, Compositions and Methods of Use to Treat Spinal Fusions
#61METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES
#62Controlled-release PTH compound
#63USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
#64Process of making abaloparatide
#65SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF
#66IMPROVEMENT OF PHYSICAL AND MENTAL WELL-BEING OF PATIENTS WITH HYPOPARATHYROIDISM
#67TREATMENT OF LONG BONE FRACTURES WITH ABALOPARATIDE
#68METHODS OF STIMULATING BONE GROWTH WITH ABALOPARATIDE AND DENOSUMAB
#69MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS
#70USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
#71Dosage Regimen for a Controlled-Release PTH Compound
#72METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES
#73THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#74DELIVERY DEVICES AND METHODS FOR MAKING THE SAME
#75Abaloparatide formulations and methods of testing, storing, modifying, and using same
#76FORMULATIONS OF PTHrP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF
#77Controlled-release PTH compound
#78METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOGULIN FC FRAGMENT LINKAGE
#79PTH compounds with low peak-to-trough ratios
#80METHODS OF TREATING LEFT VENTRICLE HYPERTROPHY
#81Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same
#82DELIVERY DEVICES AND METHODS FOR MAKING THE SAME
#83TREATMENT OF OSTEOGENESIS IMPERFECTA
#84PTH prodrugs
#85Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
#86STABLE PEPTIDE FORMULATIONS FOR ORAL USE
#87Abaloparatide formulations and methods of testing, storing, modifying, and using same
#88METHOD AND DEVICE FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE USING A MICROPROJECTION ARRAY
#89THERAPEUTIC COMPOSITION AND ADMINISTRATION METHODS FOR INCREASING OSSEOINTEGRATION WITH DENTAL IMPLANTS, GRAFT MATERIALS AND PRF
#90TREATMENT AND PREVENTION OF OSTEOPOROSIS IN HIGH BODY MASS INDEX INDIVIDUALS
#91Pharmaceutical compositions and related methods of delivery
#92Pharmaceutical compositions and related methods of delivery
#93Use of probiotic yeast cells producing recombinant parathormone for therapeutic purposes
#94PEPTIDE PHARMACEUTICALS
#95ORAL PHARMACEUTICAL COMPOSITION INCLUDING TERIPARATIDE AND METHOD FOR PREPARING SAME
#96Swallowable drug delivery device and methods of drug delivery
#97PULMONARY PHARMACEUTICAL FORMULATIONS
#98Pharmaceutical compositions for delivery of peptide
#99COMPOSITION COMPRISING RECOMBINANT PARATHYROID HORMONE FOR HEALING AFTER ROTATOR CUFF REPAIR
#100RANK ANTAGONISTS AND USES THEREOF
#101USE OF COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING BONE LOSS DISORDERS, COMPRISING CYCLO-HISPRO (CHP) AND PARATHYROID HORMONE
#102PARATHYROID HORMONE FUSION POLYPEPTIDE
#103METHODS OF IMPROVING SPINAL FUSION WITH ABALOPARATIDE
#104PARATHYROID HORMONE DERIVATIVE IN DIMERIC FORM OF PARATHYROID HORMONE FRAGMENT AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BONE DISEASES COMPRISING SAME
#105ORAL FORMULATION AND TREATMENT OF PTH ANALOG
#106Stable Therapeutic Formulations
#107USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
#108CELLS EXPRESSING PARATHYROID HORMONE 1 RECEPTOR AND USES THEREOF
#109COMPOSITION FOR IMPROVED BONE FRACTURE HEALING
#110Liquid Pharmaceutical Formulations of PTH Conjugates
#111PTH Prodrugs
#112Abaloparatide formulations and methods of testing, storing, modifying, and using same
#113Solid formulation
#114TRANSDERMAL SYSTEM FOR THE DELIVERY OF ABALOPARATIDE AND METHOD OF USE FOR TREATING OSTEOPOROSIS
#115FORMULATIONS OF ABALOPARATIDE, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF
#116METHOD OF DRUG FORMULATION BASED ON INCREASING THE AFFINITY OF ACTIVE AGENTS FOR CRYSTALLINE MICROPARTICLE SURFACES
#117FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE
#118FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS
#119FRACTURE TARGETED BONE REGENERATION THROUGH PARATHYROID HORMONE RECEPTOR STIMULATION
#120MicroRNA 19A/19B for use in treating a pathological condition associated with bone loss or reduced muscle function
#121Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week
#122Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
#123ORAL MUCOSAL DELIVERY SYSTEMS COMPRISING MONOPHASIC CONCENTRATE OF TERIPARATIDE
#124HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS
#125THERAPEUTIC AGENT FOR CARTILAGE-RELATED DISEASE
#126PARATHYROID HORMONE AND REGENERATION OF DEGENERATIVE DISCS DISEASE
#127TERIPARATIDE-CONTAINING LIQUID PHARMACEUTICAL COMPOSITION HAVING EXCELLENT STABILITY
#128Starting Dose of PTH Conjugates
#129Compositions and methods to suppress tumor growth in bone, prevent cachectic muscle loss, and preserve skeletal integrity
#130Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#131IMPROVED PEPTIDE PHARMACEUTICALS
#132METHOD FOR PREVENTING OR TREATING OSTEOPOROSIS, CHARACTERIZED BY ADMINISTERING TERIPARATIDE OR SALT THEREOF AT A FREQUENCY OF TWICE A WEEK
#133Liquid polymer delivery system for extended administration of drugs
#134METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
#135Teriparatide Use for Bone Stress Fractures/Reactions
#136Parathyroid hormone polypeptide conjugates and methods of their use
#137Method and device for transdermal delivery of parathyroid hormone using a microprojection array
#138Pharmaceutical compositions and related methods of delivery
#139PTH PRODRUGS
#140USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
#141Materials and methods for suppressing and/or treating bone related diseases and symptoms
#142PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS
#143PTH PRODRUGS
#144Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
#145CLEC11A is a bone growth agent
#146Device, system and methods for the oral delivery of therapeutic compounds
#147IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
#148TERIPARATIDE-CONTAINING LIQUID PHARMACEUTICAL COMPOSITION HAVING EXCELLENT PHARMACOKINETICS AND/OR SAFETY
#149TERIPARATIDE-CONTAINING LIQUID PHARMACEUTICAL COMPOSITION HAVING EXCELLENT STABILITY
#150PTH Prodrugs
#151Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration
#152Swallowable drug delivery device and methods of drug delivery
#153Formulations of abaloparatide, transdermal patches thereof, and uses thereof
#154Parathyroid hormone fusion polypeptide
#155Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#156Formulations for oral administration of active agents
#157Pharmaceutical compositions for delivery of peptide
#158Pharmaceutical composition and biomaterial comprising fusion peptide in which bone tissue-selective peptide bound to parathyroid hormone (PTH) or fragment thereof
#159USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
#160Abaloparatide formulations and methods of testing, storing, modifying, and using same
#161MicroRNA 19a/19b for use in treating a pathological condition associated with bone loss or reduced muscle function
#162Dosage regimen for a controlled-release PTH compound
#163Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#164PARATHYROID HORMONE AND REGENERATION OF DEGENERATIVE DISCS DISEASE
#165TREATMENTS FOR HEART FAILURE AND CARDIAC ISCHAEMIC REPERFUSION INJURY
#166Heat-stable dry powder pharmaceutical compositions and methods
#167Fusion proteins of collagen-binding domain and parathyroid hormone
#168Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
#169SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF
#170Delivery devices and methods for making the same
#171METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
#172Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
#173PTH compounds with low peak-to-trough ratios
#174Delivery of therapeutic agents by a collagen binding protein
#175Incremental Dose Finding in Controlled-Release PTH Compounds
#176Formulations for oral administration of active agents
#177Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#178SOLVENT-CAST MICROPROTRUSION ARRAYS CONTAINING ACTIVE INGREDIENT
#179Swallowable drug delivery device and methods of drug delivery
#180Swallowable drug delivery device and methods of drug delivery
#181Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#182COMBINATION OF CALCIUM-PHOSPHATE-CONTAINING POROUS COMPOSITE AND PTH
#183Fusion proteins of collagen-binding domain and parathyroid hormone
#184PREPARATION METHOD OF SUSTAINED-RELEASE MICROPARTICLES
#185Formulations of abaloparatide, transdermal patches thereof, and uses thereof
#186FORMULATIONS OF PTHRP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF
#187METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS
#188Swallowable drug delivery device and method of delivery
#189PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#190Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
#191PEPTIDE PHARMACEUTICALS
#192ANTI-BACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION
#193Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
#194Solid formulation
#195Peptide pharmaceuticals
#196Pharmaceutical formulations for the oral delivery of peptide drugs
#197Freeze-dried preparation containing high-purity PTH and method for producing same
#198PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY
#199Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#200Heat-stable dry powder pharmaceutical compositions and methods
#201Liquid polymer delivery system for extended administration of drugs
#202Agent for preventing onset of idiopathic osteonecrosis of femoral head and/or suppressing progress of same
#203Novel Formulations of PTHrP Analogue
#204CLEC11a is a bone growth agent
#205Therapeutic agent preparations into a lumen of the intestinal tract using a swallowable drug delivery device
#206TREATMENT OF HYPOPARATHYROIDISM
#207COMPOUNDS AND METHODS FOR MODULATING PHARMACOKINETICS
#208FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE
#209TREATMENT OF BONE FRACTURES AND DEFECTS
#210TREATMENT OF OSTEOPOROSIS
#211Formulations for oral administration of active agents
#212Device, system and methods for the oral delivery of therapeutic compounds
#213USES OF A PTHrP ANALOGUE IN REDUCING FRACTURE RISK
#214Cells expressing parathyroid hormone 1 receptor and uses thereof
#215PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS
#216Method of bone regeneration or bone augmentation
#217Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
#218METHOD AND DEVICE FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE USING A MICROPROJECTION ARRAY
#219Microneedle device having a peptide therapeutic agent and an amino acid and methods of making and using the same
#220Delivery of therapeutic agents by a collagen binding protein
#221METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
#222Stable therapeutic formulations
#223Method for non surgical repair of vertebral compression fractures
#224PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#225Delivery of therapeutic agents by a collagen binding protein
#226COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER
#227Fusion proteins of collagen-binding domain and parathyroid hormone
#228Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
#229USES OF A PTHrP ANALOGUE IN REDUCING FRACTURE RISK
#230Swallowable drug delivery device and methods of drug delivery
#231Stable formulations for parenteral injection of peptide drugs
#232Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
#233FGFR inhibitor for use in the treatment of hypophosphatemic disorders
#234Amine pegylation methods for the preparation of site-specific protein conjugates
#235Method of drug formulation
#236Pharmaceutical microemulsion immobilized in a thin polymer matrix and methods of making them
#237Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof
#238TREATMENT FOR NICOTINE-INDUCED LUNG DISEASE USING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AGONISTS
#239COMPOITIONS AND METHODS FOR MODULATING THERMOGENESIS USING PTH-RELATED AND EGF-RELATED COMPOUNDS
#240Pharmaceutical compositions and related methods of delivery
#241Heat-stable dry powder pharmaceutical compositions and methods
#242PROTEINS AND PROTEIN CONJUGATES WITH INCREASED HYDROPHOBICITY
#243Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
#244PULMONARY PHARMACEUTICAL FORMULATIONS
#245Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
#246Freeze-dried preparation containing high-purity PTH and method for producing same
#247COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER
#248COMBINATION THERAPY TO IMPROVE SOFT TISSUE HEALING, FAT GRAFT HEALING, ENDOCHONDRAL BONE HEALING AND OSTEOINTEGRATION
#249Increasing drug affinity for crystalline microparticle surfaces
#250Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
#251Peptide pharmaceuticals
#252Solvent-cast microprotrusion arrays containing active ingredient
#253Fusion proteins of collagen-binding domain and parathyroid hormone
#254METHODS AND COMPOSITIONS FOR EXPANDING HEMATOPOIETIC STEM AND PROGENITOR CELLS
#255Pharmaceutical composition
#256Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
#257METHOD FOR TREATING BONE LOSS USING PARATHYROID HORMONE
#258Formulations involving solvent/detergent-treated plasma (S/D plasma) and uses thereof
#259Compounds and methods for modulating pharmacokinetics
#260Intradermal delivery of substances
#261Targeted therapeutics
#262Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#263Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
#264FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS
#265COMBINATION THERAPY TO IMPROVE JOINT, TENDON, AND LIGAMENT HEALING
#266Delivery of therapeutic agents by a collagen binding protein
#267Compositions and methods for promoting bone formation
#268Pharmaceutical compositions and related methods of delivery
#269Peptide pharmaceuticals
#270Swallowable drug delivery device and method of delivery
#271STABILIZED PTH FORMULATION
#272Alpha-/beta-polypeptide analogs of parathyroid hormone (PTH) and method of using same
#273Delivery of therapeutic agents by a collagen binding protein
#274PTH-CONTAINING THERAPEUTIC/PROPHYLACTIC AGENT FOR OSTEOPOROSIS, CHARACTERIZED IN THAT PTH IS ADMINISTERED ONCE A WEEK IN A UNIT DOSE OF 100 TO 200 UNITS
#275Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
#276Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
#277Peptide pharmaceutical for oral delivery
#278Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
#279Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
#280Stable therapeutic formulations
#281Method for delivering a therapeutic agent into the wall of the small intestine
#282METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES
#283PTH-CONTAINING THERAPEUTIC/PROPHYLACTIC AGENT FOR OSTEOPOROSIS, CHARACTERIZED IN THAT PTH IS ADMINISTERED ONCE A WEEK IN A UNIT DOSE OF 100 TO 200 UNITS
#284NANOPARTICLE PEPTIDE COMPOSITIONS
#285Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#286Device, system and methods for the oral delivery of therapeutic compounds
#287Swallowable drug delivery device and methods of drug delivery
#288Phospholipid-based powders for drug delivery
#289Method for altering drug pharmacokinetics based on medical delivery platform
#290Mucosal delivery of drugs
#291Stable formulations for parenteral injection of peptide drugs
#292Stable formulations for parenteral injection of peptide drugs
#293Stable formulations for parenteral injection of peptide drugs
#294FREEZE-DRIED PREPARATION CONTAINING HIGH-PURITY PTH AND METHOD FOR PRODUCING SAME
#295Protecting and repairing cartilage and musculoskeletal soft tissues
#296Method Of Drug Delivery For PTH, PTHrP And Related Peptides
#297Method Of Drug Delivery For PTH, PTHrP And Related Peptides
#298Swallowable drug delivery device and method of delivery
#299Fusion proteins of collagen-binding domain and parathyroid hormone
#300Solvent-cast microprotrusion arrays containing active ingredient